Research Article
Health Care Costs Associated with Ankylosing Spondylitis in Turkey: An Analysis from Nationwide Real-World Data
Table 3
Marginal effects calculated after generalized linear model estimation.
| | Prevalent cases | Incident cases | | € | value | € | value |
| Age 18–39 | −320 |
0.227
| −1040 |
0.045
| Age 40–64 | −155 |
0.555
| −673 |
0.144
| Age 65+ | Reference | Reference | Female | −70 |
0.456
| −177 |
0.332
| Region | | | | | Eastern Anatolia region |
226
|
0.622
|
402
|
0.707
| Southeastern Anatolia region | Reference | Reference | Marmara region | −203 |
0.549
| −282 |
0.740
| Aegean region | −204 |
0.481
| −633 |
0438
| Mediterranean region | −350 |
0.312
| −513 |
0.534
| Black Sea region | −150 |
0.698
| −178 |
0.839
| Central Anatolia region |
48
|
0.890
| −13 |
0.987
| Elixhauser index 2
|
129
| | |
0.669
| Individual comorbidities | | | | | Diabetics |
184
|
0.238
| −46 |
0.906
| Respiratory |
288
|
0.002
|
168
|
0.428
| Allergy | −187 |
0.336
| −234 |
0.442
| Cardiovascular |
131
|
0.234
|
320
|
0.243
| Medications | | | | | Biologics |
6258
|
0
|
5518
|
0.000
| NSAIDs | −53 |
0.588
| −263 |
0.239
| DMARDs | −56 |
0.599
|
101
|
0.653
|
|
|
NSAIDs: nonsteroidal anti-inflammatory drugs; DMARDs: disease-modifying antirheumatic drugs.
|